Leukemia Research
Volume 26, Issue 3 , Pages 229-234 , March 2002

Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas

Received 27 March 2001 ,Accepted 6 June 2001.

References 

  1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 1993;328:1023
  2. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. 1992;327:1342
  3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993;328:1002
  4. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987.
  5. Philip T, Guglielmi C, Hagenbeek A, Somers R, von der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995;333:1540
  6. Skeel RT. Biologic and pharmacologic basis of cancer chemotherapy. In:  Skeel RT editors. Handbook of cancer chemotherapy. 5th ed.. Philadelphia, PA: Lippincott Williams and Wilkins; 1995;p. 3
  7. Barker HF, Jan-Mohamed RMI, Leyland MJ, Milligan DW. Mitoxantrone, etoposide and prednisolone — a novel combination in the treatment of relapsed and refractory lymphoma. Leuk. Lymphoma. 1990;2:81
  8. Santini G, Contu A, Porcellini A, Chisesi T, Coser P, Congiu AM, et al. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the non-Hodgkin's lymphoma co-operative study group (NHLCSG). Haematologica. 1991;76:485
  9. Salvagno L, Contu A, Bianco A, Endrizzi L, Schintu GM, Olmeo N, et al. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann. Oncol. 1992;3:833
  10. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol. 1997;34:40
  11. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Pharma Group. Blood. 1998;92:3562
  12. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1987;316:1493
  13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207
  14. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361
  15. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Int. Med. 1985;102:596
  16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958;53:457
  17. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J. Clin. Oncol. 2000;18:3633
  18. Brusamolino E, Bertini M, Guidi S, Vitolo U, Inverardi M, Merante S, et al. CHOP versus CNOP (N-mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficiency and toxicity. Haematologica. 1988;73:217
  19. Ho AD, del Valle F, Ruckle H, Schwammborn J, Schlimok G, Hiddemann W, et al. Mitoxantrone and high-dose cytarabine salvage therapy for refractory non-Hodgkin's lymphoma. Cancer. 1989;64:1388
  20. Gherlinzoni F, Guglielmi C, Mazza S, Amadori S, Mandelli F. Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Semin. Oncol. 1990;17(suppl. 10):3
  21. Sonneveld P, Michiels JJ. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br. J. Cancer. 1990;61:105
  22. Pavlovsky S, Santarcelli MT, Erazo A, Diaz Maqueo J, Somoza N, Leuesma Gonalono M, et al. Results of a randomized study of previously untreated intermediate- and high-grade lymphoma using CHOP versus CNOP. Ann. Oncol. 1992;3:205
  23. Bezwoda W, Rastogi RB, Erazo A, Diaz-Maquco JC, Pavlovsky S, Morioka H, Resegotti L, Rucekle H, Somoza N, Moreno-Nogucira JA, Bernasconi C, Ho A, Burns I, Lardinois J, van der Merwe A, Richard C and the Novantrone International Study Group. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Eur J Cancer 1995;31A:903.
  24. Tirelli U, Errante D, Spina M, Gastaldi R, Nigra E, Nosari AM, et al. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma. Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer. 1996;77:2127
  25. Tirelli U, Errante D, van Glabbeke M, Teodorovic I, Kluin-Nrlemans JC, Thomas J, et al. CHOP is the standard regimen in patients >70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European organization for research and treatment of cancer lymphoma cooperative study group. J. Clin. Oncol. 1998;16:27
  26. D'Incalci M, Farina P, Sessa P, Sessa C. Pharmacokinetics of VP 16–213 given by different administration methods. Cancer Chemother. Pharmacol. 1982;7:141
  27. Canetta R, Bragman K, Smaldone L, Rozeneneweig M. Carboplatin: current status and future prospects. Cancer Treat Rev. 1988;15(suppl. B):17
  28. Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin. Pharmacokinet. 1989;8:274
  29. Fields KK, Elfenbein GJ, Saleh RA, Zorsky PE, Janssen WE, Perkins JB, et al. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol. Oncol. 1992;10:61
  30. Kano Y, Akutsu M, Suzuki K, Yoshida M. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk. Res. 1993;17:113

PII: S0145-2126(01)00114-X

Leukemia Research
Volume 26, Issue 3 , Pages 229-234 , March 2002

Article Tools

* Image Usage & Resolution